Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and SAbR in Recurrent Ovarian Cancer
NCT03312114Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in epithelial ovarian cancer (EOC), primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC), sponsored by UT Southwestern Medical Center. Started Nov 2017; status: terminated.
02
Drugs
avelumab
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03312114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03312114.